Abstract
We previously reported very low levels of dopamine in post-mortem striatum of chronic methamphetamine users, raising the possibility that restoration of normal dopamine levels could help in this addiction and perhaps prevent early relapse. To establish relevance of this finding to the living brain, we tested whether striatal [11C]-(+)-dihydrotetrabenazine binding, a vesicular monoamine transporter probe sensitive to changes in (stored) vesicular dopamine, is elevated in methamphetamine users. Chronic methamphetamine users underwent [11C]-(+)-dihydrotetrabenazine positron emission tomography scans during early (mean 2.6 days) and later (~10 days) abstinence. Striatal [11C]-(+)-dihydrotetrabenazine binding was elevated (suggesting low stored dopamine) in methamphetamine users (n=28; 2.6 days after last use) relative to controls (n=22) (+28%, p<0.0001) and correlated with severity and recency of drug use and with cognitive impairment and withdrawal symptoms. Mean [11C]-(+)-dihydrotetrabenazine binding levels in the subgroup of methamphetamine users who could remain abstinent ~10 days following last use (n=17) were normal at the follow-up scan. Our imaging data support post-mortem findings and suggest that chronic methamphetamine users have low brain levels of stored dopamine during very early abstinence from MA, which could contribute to behavioral and cognitive deficits. Findings also suggest a rapid recovery of stored dopamine in some methamphetamine users who become abstinent and who therefore might not benefit from dopamine replacement medication (eg, levodopa). Further study is necessary to establish whether those users who could not maintain abstinence for the second scan might have a more severe and persistent dopamine deficiency and who could benefit from this medication.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Boileau I, Houle S, Rusjan PM, Furukawa Y, Wilkins D, Tong J et al (2010). Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans. Synapse 64: 417–420.
Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P et al (2008). Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28: 9850–9856.
Chan GL, Holden JE, Stoessl AJ, Samii A, Doudet DJ, Dobko T et al (1999). Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 40: 283–289.
de La Fuente-Fernandez R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB et al (2003). VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 49: 20–28.
de la Fuente-Fernandez R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ (2009). Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 63: 713–716.
Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF (1997). Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imag 16: 145–158.
Ehringer H, Hornykiewicz O (1960). Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menches und ihr verhalten bei erkrankungen des extrapyramiden systems. Klin Wochenschr 38: 1236–1239.
First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID/NP) New York: Biometrics Research, New York State Psychiatric Institute; (November 2002).
Frey KA, Koeppe RA, Kilbourn MR (2001). Imaging the vesicular monoamine transporter. Adv Neurol 86: 237–247.
Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S et al (1996). Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40: 873–884.
Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279–287.
Hornykiewicz O (2001). Dopamine and Parkinson’s disease. A personal view of the past, the present, and the future. Adv Neurol 86: 1–11.
Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J et al (2006). Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology 185: 327–338.
Kalasinsky KS, Hugel J, Kish SJ (2004). Use of MDA (the ‘love drug’) and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci 49: 1106–1112.
Kaye S, Darke S (2002). Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. Addiction 97: 727–731.
Kilbourn MR, Butch ER, Desmond T, Sherman P, Harris PE, Frey KA (2010). In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl Med Biol 37: 3–8.
Kish SJ (2008). Pharmacologic mechanisms of crystal meth. Cmaj 178: 1679–1682.
Kish SJ (2014) Chapter 08: The Pathology of Methamphetamine Use in the Human Brain From: The Effects of Drug Abuse on the Human Nervous System, edited by Bertha Madras and Michael Kuhar. Elsevier: Amsterdam, The Netherlands.
Kitamura O, Tokunaga I, Gotohda T, Kubo S (2007). Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Legal Med 121: 163–168.
Koeppe RA, Frey KA, Vander Borght TM, Karlamangla A, Jewett DM, Lee LC et al (1996). Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab 16: 1288–1299.
Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4 (Part 1): 153–158.
Lees AJ, Tolosa E, Olanow CW (2014). Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord 30: 19–36.
Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285–300.
McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J et al (2008). Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62: 91–100.
McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998). Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18: 8417–8422.
McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM (2005). The nature, time course and severity of methamphetamine withdrawal. Addiction 100: 1320–1329.
Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ et al (2004). Why is parkinsonism not a feature of human methamphetamine users? Brain 127 (Part 2): 363.
Nandhagopal R, Kuramoto L, Schulzer M, Mak E, Cragg J, McKenzie J et al (2011). Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 134 (Pt 11): 3290–3298.
Narendran R, Lopresti BJ, Martinez D, Mason NS, Himes M, May MA et al (2012). In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry 169: 55–63.
Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006). Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319: 237–246.
Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F et al (2006). An automated method for the extraction of regional data from PET images. Psychiatry Res 147: 79–89.
Seiden LS, Ricaurte GA (1987) Neurotoxicity of Methamphetamine and Related Drugs. Raven: New York, NY.
Taylor AE, Saint-Cyr JA (1995). The neuropsychology of Parkinson's disease. Brain Cogn 28: 281–296.
Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2009). Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J Neurochem 109: 1745–1755.
Tong J, Boileau I, Furukawa Y, Chang LJ, Wilson AA, Houle S et al (2011). Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab 31: 2065–2075.
Tong J, Fitzmaurice P, Furukawa Y, Schmunk GA, Wickham DJ, Ang LC et al (2014). Is brain gliosis a characteristic of chronic methamphetamine use in the human? Neurobiol Dis 67: 107–118.
Tong J, Wilson AA, Boileau I, Houle S, Kish SJ (2008). Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 62: 873–876.
Topp L, Mattick RP (1997). Validation of the amphetamine dependence syndrome and the SAmDQ. Addiction 92: 151–162.
Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K (1995). The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 294: 577–583.
Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M et al (2001a). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21: 9414–9418.
Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D et al (2001b). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377–382.
Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D et al (2012). Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry 17: 918–925.
Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996a). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699–703.
Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F et al (1996b). Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40: 428–439.
Wilson JM, Levey AI, Rajput A, Ang L, Guttman M, Shannak K et al (1996c). Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson’s disease. Neurology 47: 718–726.
Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G et al (2010). Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 105: 1809–1818.
Acknowledgements
This work was supported by US NIH NIDA DA25096 to SJK.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Supplementary information
Rights and permissions
About this article
Cite this article
Boileau, I., McCluskey, T., Tong, J. et al. Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence. Neuropsychopharmacol 41, 1179–1187 (2016). https://doi.org/10.1038/npp.2015.267
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/npp.2015.267
This article is cited by
-
Sex differences in neurobehavioral consequences of methamphetamine exposure in adult mice
Psychopharmacology (2022)
-
Altered patterns of fractional amplitude of low-frequency fluctuation and regional homogeneity in abstinent methamphetamine-dependent users
Scientific Reports (2021)
-
Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users
Neuropsychopharmacology (2016)
